Evidence map›Paper›PMID 29577356›Full record

ArticleThe Prostate2018

Ser-486/491 phosphorylation and inhibition of AMPKα activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.

Melissa A Babcook, Mahmut Akgul, Seunghee Margevicius, Gregory T MacLennan, Pingfu Fu, Robert Abouassaly, Sanjay Gupta

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Melissa A BabcookThe James and Eilleen Dicke Laboratory, Department of Urology, Case Western Reserve University, Cleveland, Ohio.
Mahmut AkgulDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Seunghee MargeviciusDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio.
Gregory T MacLennanDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Pingfu FuDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio.
Robert AbouassalyThe James and Eilleen Dicke Laboratory, Department of Urology, Case Western Reserve University, Cleveland, Ohio.
Sanjay GuptaThe James and Eilleen Dicke Laboratory, Department of Urology, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0002-9492-3249
University Hospitals of Cleveland · USCase Western Reserve University · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Prostate Cancer Chemoprevention by ApigeninR01CA108512 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GUPTA, SANJAY · 2004 to 2014
$2.4M
Case Urology Translational Research Training Program (CUTRTP)T32DK091213 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI DANESHGARI, FIROUZ · 2012 to 2016
$1.1M
Targeting EZH2 in Prostate Cancer by LuteolinI01BX002494 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI GUPTA, SANJAY · 2015 to 2018
–
BLRD VA I01 BX002494NCATS NIH HHS UL1 TR000439NCI NIH HHS R01 CA108512NIDDK NIH HHS T32 DK091213
6 · The paper itself

Abstract

backgroundWe previously demonstrated that adenosine monophosphate-activated protein kinase (AMPKα) activity is significantly inhibited by Ser-486/491 phosphorylation in cell culture and in vivo models of metastatic and castration-resistant prostate cancer, and hypothesized these findings may translate to clinical specimens.

methodsIn this retrospective, single-institution pilot study, 45 metastatic prostate cancer cases were identified within the University Hospitals Cleveland Medical Center Pathology Archive with both metastasis and matched primary prostate tumor specimens in formalin-fixed, paraffin-embedded blocks, and complete electronic medical records. Thirty non-metastatic, hormone-dependent prostate cancer controls, who were progression-free as defined by undetectable prostate specific antigen for at least 79.6 months (range 79.6-136.0 months), and matched metastatic cases based on age, race, and year of diagnosis. All specimens were collected from 1991 to 2014; primary tumor specimens were obtained via diagnostic biopsy or prostatectomy, and metastasis specimens obtained via surgery or perimortem. 5-μ sequential slides were processed for phospho-Ser-486/491 AMPKα

resultsIncreased inhibitory Ser-486/491 AMPKα

conclusionsp-Ser-486/491 AMPKα

Indexed as

AgedAMP-Activated Protein KinasesBiomarkers, TumorEukaryotic Initiation Factor-3HumansMaleMiddle AgedNeoplasm MetastasisPhosphorylationPilot ProjectsProstatic Neoplasms, Castration-ResistantRetrospective StudiesAMP-Activated Protein KinasesBiomarkers, TumorEIF3A protein, humanEukaryotic Initiation Factor-3AMP-activated protein kinasecastration-resistant prostate cancerclinical specimensmetastasispathologyprostatic neoplasms

Identifiers

PMID29577356
PMCPMC6591712
OpenAlexW2790670898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.